CoChat

Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies

Open access
Aune, Dagfinn, Sen, Abhijit, Norat, Teresa, Riboli, Elio, Folseraas, Trine · 2021 · Scientific Reports

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

A diagnosis of primary sclerosing cholangitis (PSC) has been associated with increased risk of hepatobiliary cancers, colorectal cancer and all-cause mortality in several studies, while associations with cardiovascular disease have been inconsistent. We conducted a systematic review and meta-analysis of published cohort studies on the topic to summarize these associations. PubMed and Embase databases were searched up to January 13th, 2020. Cohort studies on PSC and risk of cancer, cardiovascular disease, or mortality were included. Summary relative risks (RRs) and 95% confidence intervals (95% CIs) were estimated using random effects models. The summary RR (95% CI) comparing persons with PSC to persons without PSC was 584.37 (269.42–1267.51, I 2 = 89%, n = 4) for cholangiocarcinoma (CCA), 155.54 (125.34–193.02, I 2 = 0%, n = 3) for hepatobiliary cancer, 30.22 (11.99–76.17, I 2 = 0%, n = 2) for liver cancer, 16.92 (8.73–32.78, I 2 = 88%, n = 4) for gastrointestinal cancer, 7.56 (2.42–23.62, I 2 = 0%, n = 3) for pancreatic cancer, 6.10 (4.19–8.87, I 2 = 14%, n = 7) for colorectal cancer (CRC), 4.13 (2.99–5.71, I 2 = 80%, n = 5) for total cancer, 3.55 (2.94–4.28, I 2 = 46%, n = 5) for all-cause mortality, and 1.57 (0.25–9.69, I 2 = 79%, n = 2) for cardiovascular disease. Strong positive associations were observed between PSC and risk of CCA, hepatobiliary cancer, liver cancer, gastrointestinal cancer, pancreatic cancer, CRC, total cancer, and all-cause mortality, but not for cardiovascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-021-90175-w

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow-chart of study selection.
Figure 1 Flow-chart of study selection.CC BY · PubMed Central
Figure 2 Primary sclerosing cholangitis and cancer, cardiovascular disease and all-cause mortality. Summary relative risks for each outcome are represented by the squares and the 95% confidence intervals are represented by the lines through the squares (n = number of studies).
Figure 2 Primary sclerosing cholangitis and cancer, cardiovascular disease and all-cause mortality. Summary relative risks for each outcome are represented by the squares and the 95% confidence intervals are represented by the lines through the squares (n = number of studies).CC BY · PubMed Central
Figure 3 Primary sclerosing cholangitis and cholangiocarcinoma, hepatobiliary cancer, liver cancer and gastrointestinal cancer overall.
Figure 3 Primary sclerosing cholangitis and cholangiocarcinoma, hepatobiliary cancer, liver cancer and gastrointestinal cancer overall.CC BY · PubMed Central
Figure 4 Primary sclerosing cholangitis and pancreatic cancer, colorectal cancer, total cancer and all-cause mortality.
Figure 4 Primary sclerosing cholangitis and pancreatic cancer, colorectal cancer, total cancer and all-cause mortality.CC BY · PubMed Central
Figure 5 Primary sclerosing cholangitis and cardiovascular disease.
Figure 5 Primary sclerosing cholangitis and cardiovascular disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 40

Metadata

Authors
Aune, D., Sen, A., Norat, T., Riboli, E., & Folseraas, T.
Affiliations
  • Oslo University Hospital (NO)
  • Norwegian University of Science and Technology (NO)
  • Imperial College London (GB)
Corresponding author
Aune, Dagfinn
Venue
Scientific Reports
Published
2021-05-20
Volume
11
Issue
1
Pages
10646-10646
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3161880169
Cited by
40
References
48
Citations by year
2026: 3 · 2025: 10 · 2024: 12 · 2023: 7 · 2022: 6 · 2021: 2
FWCI
0.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Raagholtstiftelsen
  • Helse Sør-Øst RHF (2017076)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
primary sclerosing cholangitis, cholangiocarcinoma, hepatobiliary cancer, colorectal cancer, pancreatic cancer, liver cancer, gastrointestinal cancer, all-cause mortality, cardiovascular disease, cancer risk, mortality risk, bile duct diseases, inflammatory bowel disease, inflammatory myofibroblastic tumor
MeSH terms
Cardiovascular Diseases, Humans, Neoplasms, Risk, Risk Factors, Cholangitis, Sclerosing, Cohort Studies, Confidence Intervals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. https://app.cochat.ai/papers/10.1038/s41598-021-90175-w
The paper
Aune, D., Sen, A., Norat, T., Riboli, E., & Folseraas, T. (2021). Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. Scientific Reports. https://doi.org/10.1038/s41598-021-90175-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.